allogeneic mesenchymal stem cells
Phase 2Cell therapy
allogeneic mesenchymal stem cells is one of 43 small molecule programs targeting Urinary incontinence. It is currently in Phase 2.
2
Indications
6
Total Trials
2
Active Trials
42
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
49 competitors in Diabetic Foot
#DrugCompanyPhaseTrials
1Desferal
Jazz PharmaceuticalsApproved
Remodulin
United TherapeuticsApproved
Vancocin
HHikma Pharmaceuticals LLC
Approved
Januvia
ZZydus Therapeutics Inc.
Approved
Glucophage
EMD SeronoApproved
Xylocaine
MMEDRx USA, Inc.
Approved
Caverject
VViatris Specialty LLC
Approved
Esbriet
LLegacy Health System
Approved
Sporanox
SSebela Pharmaceuticals Development LLC
Approved
Inomax
MMallinckrodt
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Urinary incontinence1 trial
Ischemia1 trial
Primary Sjögren's Syndrome (pSS)1 trial
Allogeneic Mesenchymal Stem Cells Transplantation for Primary Sjögren's Syndrome (pSS)
Unknown status·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 1/2·NCT00953485·20 enrolled
1 more indication
Systemic Sclerosis1 trial
Allogeneic Mesenchymal Stem Cells Transplantation for Systemic Sclerosis (SSc)
Unknown status·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 1/2·NCT00962923·20 enrolled
Sources
References
- [1]
- [2]
- [3]
- [4]
Details